When: Close below $132 on volume OR further acquisition write-down OR Yeztugo Q3 <$950M

Then: Downgrade conviction

HOLD

• Normalize EBITDA of $3.28 billion and operating income of $2.54 billion demonstrate underlying business health despite impairment charges
• TTM free cash flow of $9.77 billion covers the $4.1 billion annual dividend more than twice over, providing dividend sustainability
• GILD trades at 14.05x forward earnings with 5.7% FCF yield and 0.336 beta in a macro environment favoring defensive quality
• MACD histogram expanding positive, 10 EMA crossed above 50 SMA, stock making higher highs/lows since July 24 low
• RSI at 63 is constructive, not overbought; death cross is a legacy artifact being repaired by price action
• Healthcare outperforming S&P 500 by 11.2 points reflects sector defensive characteristics, not crowding; GILD has lagged by 11.3 points over six months
• Acquisition impairment under ASC 805 is standard purchase accounting treatment, not a management confession
• Macro backdrop of 30-year yield at 19-year high and 85% probability of zero Fed cuts in 2026 historically favors high-quality defensive names
• Conservative recommendation is to hold and wait for either breakout above $140 or confirmed breakdown below 10 EMA rather than trim ahead of binary disclosure

→ vs aggressive: The impairment-as-confession narrative is intellectually dishonest; in-process R&D immediate expensing under ASC 805 is GAAP standard practice, not a management tell about private asset beliefs

→ vs aggressive: Technical bearishness ignores improving momentum: MACD expanding positive, 10 EMA above 50 SMA, higher highs/lows since July 24, RSI at 63 constructive not overbought

→ vs aggressive: Defensive rotation exhaustion conflates sector performance with GILD-specific positioning; GILD lagged S&P 500 by 11.3 points over six months, not at crowded long end

→ vs aggressive: Dividend income argument is not about excitement but sustainability; $9.77B FCF covering $4.1B dividends 2.4x is not a speed bump but the defensive thesis foundation

→ vs aggressive: Proposed 25-40% trim at upper Bollinger Band ahead of binary disclosure with less than one ATR stop is selling at wrong end of range with poor risk-reward

→ vs aggressive: Confusing conviction with correctness; being early on wrong side of asymmetric setup loses capital regardless of thesis quality

REDUCE

• Rejects impairment-as-confession narrative: $11.2B write-off is standard purchase accounting for pharma M&A, not management admission of overpayment
• Underlying business generated $2.54B operating income and $3.28B normalized EBITDA in same quarter as write-off
• Challenges conservative hold: 7% rally printed on 3.79M shares against 6-10M average—this is low-volume price action, not conviction buying
• Price at upper Bollinger Band on sub-average volume is a legitimate warning sign; momentum into resistance on low volume often fails
• Macro: 0.336 beta makes GILD attractive as defensive quality in rising yield environment, but 11.2 percentage point sector outperformance creates mean reversion risk
• FCF of $9.77B against $4.1B annual dividends is well-covered, but 2.37% yield is thin compensation for leveraged name with binary acquisition disclosure ahead
• Income-generating position is reason to trim rather than exit entirely
• Balanced approach: reduce exposure by 30% ahead of acquisition disclosure while preserving income-generating core
• Execution refinement: widen stop from $140.50 to $142 (current ATR of $3.79 means $140.50 is only ~0.4 ATR of risk)
• Trim target should be $140 rather than upper Bollinger Band—selling into immediate resistance often results in missed fills
• Re-engagement plan: add back on weakness toward 50 SMA at $130 if acquisition narrative disappoints, or on technical breakout

→ vs aggressive: Impairment-as-confession narrative is intellectually dishonest; $11.2B write-off is standard GAAP purchase accounting for in-process R&D, not an admission of overpayment

→ vs aggressive: High-conviction short thesis is unsupported; $2.54B operating income and $3.28B EBITDA show intact fundamental story with defensive characteristics

→ vs conservative: Complacent hold ignores legitimate technical warning: 7% rally on 3.79M shares (vs 6-10M average) is a vacuum, not conviction buying; price at upper Bollinger Band on sub-average volume

→ vs conservative: No acknowledgment of near-term event risk from binary acquisition disclosure that warrants risk reduction

→ vs conservative: Stop at $140.50 is too tight given ATR of $3.79; doesn't account for normal volatility around catalysts

→ vs conservative: Trim target at upper Bollinger Band is suboptimal; selling into immediate resistance often results in missed fills